Scope
A focused account of KDIGO’s paediatric nephrotic syndrome guidance, covering diagnosis, initial and relapse glucocorticoid regimens, steroid-sparing treatment and steroid resistance. Treatment choices depend on the child’s response, toxicity, genetic findings and access to specialist monitoring.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Population, diagnosis and response
- The guideline addresses children aged 1–18 years. A child with nephrotic syndrome below 1 year should be referred to paediatric nephrology; treatment of that age group falls outside this guideline. [1]
- Nephrotic syndrome combines nephrotic-range proteinuria with serum albumin below 30 g/L (3 g/dL), or oedema when albumin is unavailable. Nephrotic-range proteinuria includes a spot urine protein:creatinine ratio of at least 200 mg/mmol (2 g/g). [1]
- Complete remission requires first-morning or 24-hour urine protein:creatinine ratio at most 200 mg/g (0.2 g/g; 20 mg/mmol), or the stated negative/trace dipstick equivalent, for at least three consecutive days. Relapse is recurrent nephrotic-range proteinuria after complete remission. [1]
- Initial response and relapse frequency during the first year guide prognosis. Kidney biopsy is usually unnecessary at first presentation, but assess biopsy indications including presentation at age 12 years or older, treatment resistance or an atypical course. [1]
Initial glucocorticoid course
- KDIGO recommends either 8 weeks of oral glucocorticoids, with 4 weeks daily then 4 weeks on alternate days, or 12 weeks, with 6 weeks daily then 6 weeks on alternate days (strong recommendation, moderate-certainty evidence). [1]
- For initial childhood nephrotic syndrome, use oral prednisone or prednisolone 60 mg/m²/day or 2 mg/kg/day, maximum 60 mg/day, during the daily phase. During the corresponding alternate-day phase, use 40 mg/m² or 1.5 mg/kg, maximum 40 mg per dose. Use paired courses of 4 weeks daily followed by 4 weeks on alternate days, or 6 weeks daily followed by 6 weeks on alternate days. [1]
Relapse treatment and infection-associated prevention
- For a relapse, give oral prednisone or prednisolone as one daily dose of 60 mg/m²/day or 2 mg/kg/day, maximum 60 mg/day, until complete remission has lasted at least 3 days. [1]
- After complete remission during treatment of a steroid-sensitive relapse, reduce prednisone or prednisolone to 40 mg/m² or 1.5 mg/kg, maximum 40 mg, on alternate days for 4 weeks. [1]
- Subsequent relapses in frequently relapsing or steroid-dependent disease can use the same regimen when glucocorticoid toxicity is absent. With toxicity, consider a shorter taper or a more robust steroid-sparing approach. [1]
- Do not routinely add daily glucocorticoids during respiratory or other infections to prevent relapse in frequently relapsing or steroid-dependent disease (strong recommendation, low-certainty evidence). [1]
- An exception may be considered at upper respiratory infection onset: 3 extra daily doses of prednisone or prednisolone 0.5 mg/kg/day, only in frequently relapsing or steroid-dependent children already taking low-dose alternate-day prednisolone who have repeated infection-associated relapses or significant glucocorticoid morbidity. [1]
Choosing and monitoring steroid-sparing treatment
- For frequently relapsing disease without serious glucocorticoid adverse effects, low-dose alternate-day prednisone or prednisolone, optimally no more than 0.5 mg/kg per dose, can prevent relapse. [1]
- KDIGO recommends steroid-sparing agents for frequently relapsing disease with serious glucocorticoid adverse effects, and for all steroid-dependent disease, rather than glucocorticoids alone or no treatment (strong recommendation, moderate-certainty evidence). [1]
- Ideally establish remission with glucocorticoids before starting a steroid-sparing agent, and coadminister glucocorticoids for at least 2 weeks after starting it. [1]
- Choose among calcineurin inhibitors, cyclophosphamide, levamisole, mycophenolate mofetil and rituximab according to resources, adherence, adverse effects and family preferences. The listed agents do not represent a universal treatment ranking. [1]
- When oral cyclophosphamide is selected for steroid-sensitive disease, do not start before glucocorticoid-induced remission. The regimen is 2 mg/kg/day for 12 weeks, maximum cumulative 168 mg/kg. Do not give a second alkylating-agent course; check blood counts weekly and reduce or stop treatment for significant marrow suppression. [1]
- When a calcineurin inhibitor is used, balance proteinuria response against creatinine and toxicity. Reduce the dose if creatinine rises without plateauing or exceeds baseline by more than 30%; discontinue if it does not fall after dose reduction. Blood levels support adherence and toxicity monitoring; nephrotic-syndrome target ranges are not established. [1]
Steroid resistance and specialist reassessment
- Failure to remit completely after 4 weeks of standard daily glucocorticoids raises steroid resistance. Start renin–angiotensin system inhibition and pursue genetic testing and/or biopsy where available. Partial responders may remit by 6 weeks, so specialist confirmation and treatment reassessment are important. [1]
- Consider genetic disease promptly in established steroid resistance: immunosuppression may not help many genetic forms, although selected mutations can respond. Expert genetic assessment helps avoid unnecessary cumulative immunosuppression. [1]
- KDIGO recommends cyclosporine or tacrolimus as initial second-line therapy for children with steroid-resistant nephrotic syndrome (strong recommendation, low-certainty evidence). [1]
- In steroid-resistant disease treated with a calcineurin inhibitor, stop it if at least partial response has not occurred by 6 months. For responders, the guideline advises continuation for at least 12 months because relapse after discontinuation is common; continue toxicity monitoring. [1]
- Genetic testing is indicated in steroid resistance, congenital or infantile nephrotic syndrome, syndromic presentations, and a family history of steroid resistance or focal segmental glomerulosclerosis. Biopsy assessment also becomes relevant with kidney failure unrelated to hypovolaemia or falling function during calcineurin-inhibitor treatment. [1]
Limitations and use
- This summary covers selected diagnosis and treatment decisions for childhood nephrotic syndrome, not a complete protocol for oedema, infection, thrombosis or vaccination.
- Definitions of frequently relapsing and steroid-dependent disease, full drug-specific screening and monitoring schedules, and management of genetic or multidrug-resistant disease require the full guideline and paediatric nephrology assessment.
- The steroid-sparing choices and monitoring described here do not replace individual assessment of contraindications, toxicity, formulation and access to specialist care.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Nephrotic syndrome in children
Selected recommendation material consulted
Publication details
- Issuing organisation
- KDIGO
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.